Skip to main content

Scienion to Supply Protagen with Microarray Batches for Clinical Validation of Protein Biomarkers


Scienion said this week that it will provide protein microarray batches of more than 1,000 arrays to Protagen for that company's clinical validation studies of its protein biomarker panels.

According to Protagen chief scientific officer Peter Schulz-Knappe, the microarray batches will be used in "multicenter, clinical validation studies" of the company's protein biomarker panels for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer.

Additionally, the two Dortmund, Germany-based firms will collaborate under a strategic partnership to evaluate new platforms for multiplex analytics and develop new techniques that they will carry through jointly to the proof-of-concept stage.

"Scienion's sciFlexArrayer technology allows the manufacturing of protein microarray batches each with more than 3,500 single proteins in highest quality and reproducibility," Schulz-Knappe said in a statement. "Thereby, we can realize the needed consistency in quality and properties throughout three stages: from spot to spot, from array to array, and from batch to batch."

Financial and other terms of the agreement were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.